CAS |
1001350-96-4 |
Content |
Purity≥98% |
English Name |
BMS-754807 |
Synonym |
BMS754807 |
Unit |
Piece |
Purity |
≥98% |
Molecular Formula |
C23H24FN9O |
Molecular Weight |
461.49 |
Appearance |
White to off-white solid |
Storage |
Powder : -20℃, 2 years;In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO |
MDL |
MFCD18633202 |
InChIKey |
LQVXSNNAFNGRAH-QHCPKHFHSA-N |
InChI |
InChI=1S/C23H24FN9O/c1-23(21(34)26-15-7-8-18(24)25-13-15)9-3-10-32(23)22-28-20(17-4-2-11-33(17)31-22)27-19-12-16(29-30-19)14-5-6-14/h2,4,7-8,11-14H,3,5-6,9-10H2,1H3,(H,26,34)(H2,27,28,29,30,31)/t23-/m0/s1 |
PubChem CID |
24785538 |
SMILES |
FC1=CC=C(NC([C@@]2(C)N(C(N=C3NC4=NNC(C5CC5)=C4)=NN6C3=CC=C6)CCC2)=O)C=N1 |
Description |
BMS-754807 is a potent, reversible insulin-like growth factor 1 receptor/insulin receptor inhibitor. |
Target Point |
IGF-1R inhibitor |
Passage |
Protein Tyrosine Kinase/RTK |
Data Literature Source |
[1]. Carboni JM, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther, 2009, 8(12), 3341-3349.
[2]. Wittman MD, et al. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J Med Chem, 2009, 52(23), 7360-7363.
[3]. Kolb EA, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer, 2011, 56(4), 595-603.
[4]. Franks SE, et al. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes. 2016 Mar 1;9:134. |
Specification |
2mg 5mg 10mM*1mL in DMSO 10mg |